Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jun 25

PMID 32575411

Citations 28

Authors

Roseline Mazet

Josias B G Yameogo

Denis Wouessidjewe

Luc Choisnard

Annabelle Geze

Affiliations

Soon will be listed here.

Abstract

Ocular inflammation is one of the most common symptom of eye disorders and diseases. The therapeutic management of this inflammation must be rapid and effective in order to avoid deleterious effects for the eye and the vision. Steroidal (SAID) and non-steroidal (NSAID) anti-inflammatory drugs and immunosuppressive agents have been shown to be effective in treating inflammation of the ocular surface of the eye by topical administration. However, it is well established that the anatomical and physiological ocular barriers are limiting factors for drug penetration. In addition, such drugs are generally characterized by a very low aqueous solubility, resulting in low bioavailability as only 1% to 5% of the applied drug permeates the cornea. The present review gives an updated insight on the conventional formulations used in the treatment of ocular inflammation, i.e., ointments, eye drops, solutions, suspensions, gels, and emulsions, based on the commercial products available on the US, European, and French markets. Additionally, sophisticated formulations and innovative ocular drug delivery systems will be discussed. Promising results are presented with micro- and nanoparticulated systems, or combined strategies with polymers and colloidal systems, which offer a synergy in bioavailability and sustained release. Finally, different tools allowing the physical characterization of all these delivery systems, as well as in vitro, ex vivo, and in vivo evaluations, will be considered with regards to the safety, the tolerance, and the efficiency of the drug products.

Citing Articles

Ophthalmic In Situ Nanocomposite Gel for Delivery of a Hydrophobic Antioxidant.

Slavkova M, Voycheva C, Popova T, Tzankov B, Tzankova D, Spassova I Gels. 2025; 11(2).

PMID: 39996648 PMC: 11854355. DOI: 10.3390/gels11020105.

Drug delivery strategies to improve the treatment of corneal disorders.

Tafti M, Fayyaz Z, Aghamollaei H, Jadidi K, Faghihi S Heliyon. 2025; 11(2):e41881.

PMID: 39897787 PMC: 11783021. DOI: 10.1016/j.heliyon.2025.e41881.

Lipid-based nanoparticles: innovations in ocular drug delivery.

Baig M, Karade S, Ahmad A, Khan M, Haque A, Webster T Front Mol Biosci. 2024; 11:1421959.

PMID: 39355534 PMC: 11442363. DOI: 10.3389/fmolb.2024.1421959.

Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study.

Puente-Iglesias M, Cuartero-Martinez A, Tourino-Peralba R, Rodriguez-Ares M, Giraldez M, Yebra-Pimentel E Int J Mol Sci. 2024; 25(18).

PMID: 39337336 PMC: 11432331. DOI: 10.3390/ijms25189847.

Advancements and challenges in stem cell transplantation for regenerative medicine.

Wei L, Yan W, Shah W, Zhang Z, Wang M, Liu B Heliyon. 2024; 10(16):e35836.

PMID: 39247380 PMC: 11379611. DOI: 10.1016/j.heliyon.2024.e35836.

References

Patel N, Nakrani H, Raval M, Sheth N . Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Drug Deliv. 2016; 23(9):3712-3723. DOI: 10.1080/10717544.2016.1223225. View

Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso M . Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2009; 62(1):100-17. DOI: 10.1016/j.addr.2009.11.026. View

Kalam M . Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone. Int J Biol Macromol. 2016; 89:127-36. DOI: 10.1016/j.ijbiomac.2016.04.070. View

Cao F, Wang Y, Ping Q, Liao Z . Zn-Al-NO(3)-layered double hydroxides with intercalated diclofenac for ocular delivery. Int J Pharm. 2010; 404(1-2):250-6. DOI: 10.1016/j.ijpharm.2010.11.013. View

Giunchedi P, Conte U, Chetoni P, Saettone M . Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits. Eur J Pharm Sci. 1999; 9(1):1-7. DOI: 10.1016/s0928-0987(99)00023-8. View

Ke T, Graff G, Spellman J, Yanni J . Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000; 24(4):371-84. DOI: 10.1023/a:1007001131987. View

Moya-Ortega M, Alves T, Alvarez-Lorenzo C, Concheiro A, Stefansson E, Thorsteinsdottir M . Dexamethasone eye drops containing γ-cyclodextrin-based nanogels. Int J Pharm. 2012; 441(1-2):507-15. DOI: 10.1016/j.ijpharm.2012.11.002. View

Moiseev R, Morrison P, Steele F, Khutoryanskiy V . Penetration Enhancers in Ocular Drug Delivery. Pharmaceutics. 2019; 11(7). PMC: 6681039. DOI: 10.3390/pharmaceutics11070321. View

Gamisans F, Lacoulonche F, Chauvet A, Espina M, Garcia M, Egea M . Flurbiprofen-loaded nanospheres: analysis of the matrix structure by thermal methods. Int J Pharm. 1999; 179(1):37-48. DOI: 10.1016/s0378-5173(98)00381-0. View

10.

Comstock T, DeCory H . Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012; 2012:789623. PMC: 3321285. DOI: 10.1155/2012/789623. View

11.

Barile F . Validating and troubleshooting ocular in vitro toxicology tests. J Pharmacol Toxicol Methods. 2010; 61(2):136-45. PMC: 2849866. DOI: 10.1016/j.vascn.2010.01.001. View

12.

Patel S, Garapati C, Chowdhury P, Gupta H, Nesamony J, Nauli S . Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application. J Ocul Pharmacol Ther. 2015; 31(4):215-27. PMC: 11075078. DOI: 10.1089/jop.2014.0152. View

13.

Asasutjarit R, Theerachayanan T, Kewsuwan P, Veeranodha S, Fuongfuchat A, Ritthidej G . Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use. AAPS PharmSciTech. 2015; 16(5):1013-24. PMC: 4674645. DOI: 10.1208/s12249-015-0290-4. View

14.

Hui H, Robinson J . Effect of particle dissolution rate on ocular drug bioavailability. J Pharm Sci. 1986; 75(3):280-7. DOI: 10.1002/jps.2600750316. View

15.

Dong Y, Dong P, Huang D, Mei L, Xia Y, Wang Z . Fabrication and characterization of silk fibroin-coated liposomes for ocular drug delivery. Eur J Pharm Biopharm. 2015; 91:82-90. DOI: 10.1016/j.ejpb.2015.01.018. View

16.

Guengerich F . Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions. Chem Res Toxicol. 2016; 30(1):2-12. PMC: 5293730. DOI: 10.1021/acs.chemrestox.6b00226. View

17.

Kalam M . The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone. Int J Biol Macromol. 2016; 89:559-68. DOI: 10.1016/j.ijbiomac.2016.05.016. View

18.

Adibkia K, Omidi Y, Siahi M, Javadzadeh A, Barzegar-Jalali M, Barar J . Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther. 2007; 23(5):421-32. DOI: 10.1089/jop.2007.0039. View

19.

Ibrahim H, El-Leithy I, Makky A . Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm. 2010; 7(2):576-85. DOI: 10.1021/mp900279c. View

20.

Zhu H, Chauhan A . Effect of viscosity on tear drainage and ocular residence time. Optom Vis Sci. 2008; 85(8):715-25. DOI: 10.1097/OPX.0b013e3181824dc4. View